These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

862 related items for PubMed ID: 19072356

  • 1. Interaction of metabolic syndrome, nonalcoholic fatty liver disease and chronic hepatitis C.
    Rafiq N, Younossi ZM.
    Expert Rev Gastroenterol Hepatol; 2008 Apr; 2(2):207-15. PubMed ID: 19072356
    [Abstract] [Full Text] [Related]

  • 2. Non-alcoholic fatty liver disease and hepatitis C infection.
    Bondini S, Younossi ZM.
    Minerva Gastroenterol Dietol; 2006 Jun; 52(2):135-43. PubMed ID: 16557185
    [Abstract] [Full Text] [Related]

  • 3. Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin resistance and hepatic steatosis.
    Bugianesi E, Marchesini G, Gentilcore E, Cua IH, Vanni E, Rizzetto M, George J.
    Hepatology; 2006 Dec; 44(6):1648-55. PubMed ID: 17133473
    [Abstract] [Full Text] [Related]

  • 4. Hepatitis C infection and nonalcoholic fatty liver disease.
    Cheung O, Sanyal AJ.
    Clin Liver Dis; 2008 Aug; 12(3):573-85, viii-ix. PubMed ID: 18625429
    [Abstract] [Full Text] [Related]

  • 5. Review article: non-alcoholic fatty liver disease and hepatitis C--risk factors and clinical implications.
    Sanyal AJ.
    Aliment Pharmacol Ther; 2005 Nov; 22 Suppl 2():48-51. PubMed ID: 16225473
    [Abstract] [Full Text] [Related]

  • 6. Hepatitis C and nonalcoholic fatty liver disease.
    Ramesh S, Sanyal AJ.
    Semin Liver Dis; 2004 Nov; 24(4):399-413. PubMed ID: 15605308
    [Abstract] [Full Text] [Related]

  • 7. [Hepatitis C virus-associated and metabolic steatosis. Different or overlapping diseases?].
    Lonardo A, Loria P, Adinolfi LE, Andreana A, Ruggiero G, Carulli N.
    Ann Ital Med Int; 2005 Nov; 20(1):10-22. PubMed ID: 15859390
    [Abstract] [Full Text] [Related]

  • 8. Nonalcoholic fatty liver disease in patients with hepatitis C is associated with features of the metabolic syndrome.
    Sanyal AJ, Contos MJ, Sterling RK, Luketic VA, Shiffman ML, Stravitz RT, Mills AS.
    Am J Gastroenterol; 2003 Sep; 98(9):2064-71. PubMed ID: 14499789
    [Abstract] [Full Text] [Related]

  • 9. Influence of metabolic syndrome, viral genotype and antiviral therapy on superimposed fatty liver disease in chronic hepatitis C.
    Liu CJ, Jeng YM, Chen PJ, Lai MY, Yang HC, Huang WL, Kao JH, Chen DS.
    Antivir Ther; 2005 Sep; 10(3):405-15. PubMed ID: 15918331
    [Abstract] [Full Text] [Related]

  • 10. Nonalcoholic fatty liver disease.
    Angulo P.
    Rev Gastroenterol Mex; 2005 Nov; 70 Suppl 3():52-6. PubMed ID: 17471859
    [Abstract] [Full Text] [Related]

  • 11. Metabolic syndrome, non-alcoholic fatty liver disease and hepatitis C virus: impact on disease progression and treatment response.
    Younossi ZM, McCullough AJ.
    Liver Int; 2009 Mar; 29 Suppl 2():3-12. PubMed ID: 19187068
    [Abstract] [Full Text] [Related]

  • 12. From the metabolic syndrome to NAFLD or vice versa?
    Vanni E, Bugianesi E, Kotronen A, De Minicis S, Yki-Järvinen H, Svegliati-Baroni G.
    Dig Liver Dis; 2010 May; 42(5):320-30. PubMed ID: 20207596
    [Abstract] [Full Text] [Related]

  • 13. Evolving trends in nonalcoholic fatty liver disease.
    Delgado JS.
    Eur J Intern Med; 2008 Mar; 19(2):75-82. PubMed ID: 18249301
    [Abstract] [Full Text] [Related]

  • 14. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome.
    Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, Vanni E, Villanova N, Melchionda N, Rizzetto M.
    Hepatology; 2003 Apr; 37(4):917-23. PubMed ID: 12668987
    [Abstract] [Full Text] [Related]

  • 15. Nonalcoholic fatty liver disease and the metabolic syndrome.
    Marchesini G, Babini M.
    Minerva Cardioangiol; 2006 Apr; 54(2):229-39. PubMed ID: 16778754
    [Abstract] [Full Text] [Related]

  • 16. Steatosis, insulin resistance and fibrosis progression in chronic hepatitis C.
    Castera L.
    Minerva Gastroenterol Dietol; 2006 Jun; 52(2):125-34. PubMed ID: 16557184
    [Abstract] [Full Text] [Related]

  • 17. Hepatic fatty acid translocase CD36 upregulation is associated with insulin resistance, hyperinsulinaemia and increased steatosis in non-alcoholic steatohepatitis and chronic hepatitis C.
    Miquilena-Colina ME, Lima-Cabello E, Sánchez-Campos S, García-Mediavilla MV, Fernández-Bermejo M, Lozano-Rodríguez T, Vargas-Castrillón J, Buqué X, Ochoa B, Aspichueta P, González-Gallego J, García-Monzón C.
    Gut; 2011 Oct; 60(10):1394-402. PubMed ID: 21270117
    [Abstract] [Full Text] [Related]

  • 18. Role of fatty acids in the pathogenesis of obesity and fatty liver: impact of bariatric surgery.
    Verna EC, Berk PD.
    Semin Liver Dis; 2008 Nov; 28(4):407-26. PubMed ID: 18956297
    [Abstract] [Full Text] [Related]

  • 19. Recent concepts in non-alcoholic fatty liver disease.
    Adams LA, Angulo P.
    Diabet Med; 2005 Sep; 22(9):1129-33. PubMed ID: 16108837
    [Abstract] [Full Text] [Related]

  • 20. Nonalcoholic fatty liver disease (NAFLD): a comprehensive review.
    Salt WB.
    J Insur Med; 2004 Sep; 36(1):27-41. PubMed ID: 15104027
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 44.